President of Xenon Pharmaceuticals Picks Up 88% More Stock
The President of Xenon Pharmaceuticals, Ian Mortimer, recently purchased US$1.1 million worth of stock, increasing his holding by 88%. This significant insider buying activity, along with other insider purchases totaling US$3.4 million over the last year, suggests optimism within the company despite it currently making losses. While insider ownership remains low at 0.1%, the overall pattern of transactions indicates insiders anticipate a positive future for Xenon Pharmaceuticals.
Eight new Xenon employees get options to buy shares at $38.93
Xenon Pharmaceuticals granted 17,850 share options and 10,500 restricted share units to eight new non-officer employees, effective October 1, 2026. The options have an exercise price of $38.93 per common share, matching the closing price on the grant date. Both types of awards vest over four years, contingent on the employees' continued service with the company.
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
Xenon Pharmaceuticals (XENE) saw significant insider buying totaling $1.68 million by its CEO and CFO, pushing the stock up 5% for its best day in over a month. This comes as the company advances Azetukalner, its lead epilepsy drug, which was recently submitted to the FDA for focal onset seizures. Despite a Q2 net loss, Xenon maintains a strong cash position of $1.25 billion, expected to fund operations into 2029.
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $70
RBC Capital has reiterated its Buy rating on Xenon Pharmaceuticals (XENE.US) and maintained a target price of $70. This indicates a continued positive outlook on the company's stock by the investment bank.
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly Buys 15,000 Shares in Open-Market Purchase
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly purchased 15,000 shares of the company's common stock on September 30, 2026, bringing his total holdings to 15,000 shares. This transaction represents his entire buying activity over the past year and is considered a significant signal of insider sentiment, especially coming from the CFO. The article also notes that while there have been more insider sells than buys at Xenon Pharmaceuticals over the past year, Kelly's purchase, combined with a net-positive guru ownership picture, provides additional context for investors.
At $37.38 a share, Xenon Pharmaceuticals (XENE) CEO Ian Mortimer buys company stock.
Xenon Pharmaceuticals Inc. CEO Ian Mortimer purchased 30,000 common shares of XENE at $37.38 per share on September 30, 2026. This transaction increased his direct holdings to 49,923 common shares, with an additional 14,300 shares held indirectly by his spouse. No Rule 10b5-1 plan was reported for this purchase, indicating a direct insider decision.
At $37.316 each, CFO Kelly buys 15,000 Xenon Pharmaceuticals (XENE) shares.
Xenon Pharmaceuticals Inc.'s Chief Financial Officer, Thomas Patrick Kelly, purchased 15,000 Common Shares at $37.316 per share on September 30, 2026. This direct purchase brings his total direct holdings to 15,000 Common Shares, with no Rule 10b5-1 plan reported. The transaction was officially filed as a Form 4 on October 1, 2026.
Gross margin % of Xenon Pharmaceuticals Inc. – HAN:XP0
The article focuses on the gross margin percentage of Xenon Pharmaceuticals Inc. (XP0) listed on the Hannover Stock Exchange. It appears to be a financial data snippet from TradingView, indicating a market closed status with no trades. The content primarily provides navigation and legal disclaimers rather than detailed financial analysis.
Is Xenon Pharmaceuticals (XENE) Undervalued On Its FDA Filing And Psychiatry Trial Pause?
Xenon Pharmaceuticals (XENE) recently submitted a New Drug Application to the FDA for azetukalner in focal-onset seizures, while simultaneously pausing enrollment in some psychiatry trials to re-evaluate dosing. The stock has seen a significant decline, down 38.8% over the past month, as investors weigh the FDA progress against the psychiatry trial adjustments. Despite a fair value estimate suggesting it's 51.5% undervalued, the company faces challenges including unprofitability forecasts and a wide range in analyst price targets, reflecting varied opinions on its future prospects.
Total common shares outstanding of Xenon Pharmaceuticals Inc. – HAN:XP0
This article provides financial data for Xenon Pharmaceuticals Inc. (HAN:XP0), specifically focusing on its total common shares outstanding. It highlights that the information is sourced from TradingView and FactSet, emphasizing the financial aspect of the company on the Hannover Stock Exchange.
Xenon Pharmaceuticals stock trades at EUR 32.30 after trial pause
Xenon Pharmaceuticals stock traded at EUR 32.30 after a voluntary pause in new enrollment for its Phase 3 studies in major depressive disorder and bipolar depression due to neuropsychiatric adverse events. Despite analyst target cuts from Jefferies and Deutsche Bank following this pause, the company's epilepsy program continues to advance, with an NDA submitted for azetukalner in focal seizures. The stock's valuation now hinges on whether the epilepsy filing can offset the uncertainty surrounding its psychiatry development.
Xenon Pharmaceuticals Inc. (XENE) Latest Stock News & Headlines - Yahoo Finance
This Yahoo Finance page provides the latest news and headlines for Xenon Pharmaceuticals Inc. (XENE), including stock performance data, recent press releases, and analyst opinions. The stock closed at $37.25 with a 1.44% increase on September 29, 2026, though its year-to-date and 1-year returns are negative compared to the S&P 500. Recent news highlights include award recognition for an executive, an epilepsy approval pursuit, and discussions around setbacks from paused psychiatry trials.
Should NDA Filing Require Action From Xenon Pharmaceuticals (XENE) Investors?
Xenon Pharmaceuticals (XENE) has submitted a New Drug Application (NDA) to the FDA for azetukalner in focal seizures, a positive step for its epilepsy franchise. However, the company has temporarily paused enrollment in trials for major depressive disorder and bipolar depression due to neuropsychiatric side effects, which introduces uncertainty for azetukalner's broader commercial potential. Investors should monitor the FDA's response to the NDA and the progress of remaining epilepsy studies, as psychiatry indications now carry higher execution and safety risks.
Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history
Xenon Pharmaceuticals Inc. (XENE) is a neuroscience-focused biopharmaceutical company specializing in treatments for neurological and psychiatric disorders, with products like Azetukalner in Phase 3 for epilepsy and neuropsychiatric conditions. The company's stock shows a current price of $36.30, a market cap of $3.556 billion, and analyst consensus for a target price of $74.31. Financial highlights include a recent net income of -$409.2 million and total cash of $930.69 million.
Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History
This article provides comprehensive financial information for Xenon Pharmaceuticals Inc. (XENE), including its stock price, historical data, key financial metrics, and analyst insights. It details the company's focus on neurological and psychiatric disorders, its lead product candidates, and its recent performance compared to the S&P 500.
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced an investigation into Xenon Pharmaceuticals Inc. (NASDAQ: XENE) for potential securities law violations. The probe follows a 30.7% stock drop after Xenon paused enrollment in clinical studies for major depressive disorder and bipolar depression due to neuropsychiatric adverse events. SBS is encouraging affected shareholders to contact them to discuss their rights.
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
Xenon Pharmaceuticals Inc. (XENE) has submitted a New Drug Application for azetukalner for focal seizures, backed by substantial clinical evidence from Phase 2b and Phase 3 studies. However, the company has paused new enrollment in major depressive disorder and bipolar depression studies due to neuropsychiatric adverse events, raising questions about the drug's expansion beyond epilepsy. Future results from the X-NOVA2 depression trial and potential dosing changes will be crucial in determining azetukalner's broader applicability.
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
SueWallSt has announced an investigation into Xenon Pharmaceuticals (XENE) following a significant stock drop. The decline, which saw shares fall over 30%, occurred after Xenon paused new patient enrollment in its Phase 3 depression trials due to neuropsychiatric adverse events. The investigation will examine whether the company made misleading statements regarding the safety profile and clinical development of azetukalner.
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
SueWallSt has initiated an investigation into Xenon Pharmaceuticals (XENE) following a significant 30.7% stock drop. This decline occurred after Xenon paused patient enrollment in its Phase 3 azetukalner trials for major depressive disorder and bipolar depression due to neuropsychiatric adverse events. The investigation will examine whether Xenon made misleading statements regarding the drug's safety profile.
XENE Investor Alert: Levi & Korsinsky Investigates Xenon Pharmaceuticals Inc. (XENE) For Potential Securities Fraud
Levi & Korsinsky has launched an investigation into Xenon Pharmaceuticals Inc. (NASDAQ: XENE) for potential federal securities law violations. This follows a 30.17% stock drop on September 18, 2026, after the company paused new-patient enrollment in Phase 3 trials for azetukalner due to unexpected neuropsychiatric adverse events. The firm is inviting investors who suffered losses to explore potential recovery options.
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Wolf Popper LLP is investigating potential claims for purchasers of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) common stock. This investigation follows Xenon's announcement of a voluntary pause on new patient enrollment in clinical studies for major depressive disorder and bipolar depression due to neuropsychiatric adverse events, causing a significant drop in the company's stock price. Investors who suffered losses are encouraged to contact Wolf Popper LLP.
Xenon will present a drug being developed for epilepsy and two types of depression
Xenon Pharmaceuticals (Nasdaq: XENE) will participate in a virtual fireside chat at the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 23, 2026. The company will discuss its lead drug candidate, azetukalner, a KV7 potassium channel opener in late-stage clinical development for epilepsy, major depressive disorder, and bipolar depression. Xenon also has other KV7 and NaV1.7 programs in Phase 1 development for pain.
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Xenon Pharmaceuticals Inc. announced its participation in the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, where it will hold a virtual fireside chat on September 23, 2026. The neuroscience-focused biopharmaceutical company is developing azetukalner, a K V 7 potassium channel opener, for epilepsy, major depressive disorder, and bipolar depression, and has other potassium and sodium channel modulators in early-stage development for pain. Details for the presentation and webcast will be available on the Investors section of Xenon's website.
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment
Xenon Pharmaceuticals (XENE) stock dropped 31% after the company paused enrollment in its Phase 3 studies for major depressive disorder and bipolar disorder due to higher rates of neuropsychiatric side effects. While the X-NOVA2 trial for major depressive disorder is still expected to report results in Q1 2027, analysts have reacted by cutting price targets and downgrading the stock, raising concerns about the drug's psychiatric potential. The company plans to adjust dosing before potentially resuming these trials.
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data
Xenon Pharmaceuticals (XENE) shares dropped 32.2% after the company paused new enrollment in its Phase 3 major depressive disorder and bipolar depression studies due to neuropsychiatric adverse events. This decision occurred on the same day Xenon submitted a New Drug Application (NDA) to the FDA for azetukalner for focal seizures, which showed positive data. The pause in psychiatry trials is reshaping expectations for azetukalner's use beyond epilepsy and raises concerns about potential long-term safety implications.
Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge
U.S. stocks experienced a downturn, with the Dow Jones index dropping over 200 points, while the NASDAQ and S&P 500 also saw declines. Xenon Pharmaceuticals (NASDAQ: XENE) shares plunged by 29% after the company voluntarily paused enrollment for new patients in its psychiatry studies, leading multiple firms to lower their price targets. Conversely, Securitize Corp (NYSE: SECZ) and Hyperliquid Strategies Inc (NASDAQ: PURR) saw gains.
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.
Xenon Pharmaceuticals' stock plummeted 30% after the company announced it was submitting a New Drug Application for azetukalner for focal seizures, but also pausing trials for major depressive disorder and bipolar depression. This setback for Xenon could benefit a rival biotech company that has faced similar pressures. The article highlights that what should have been a milestone for Xenon was overshadowed by this clinical setback.
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause
Xenon Pharmaceuticals Inc. shares dropped 30% after the company voluntarily paused new enrollment in its major depressive disorder and bipolar depression studies. The company stated that this precautionary measure, taken in consultation with its safety monitoring board, is expected to be temporary, and ongoing epilepsy studies remain unaffected. Existing study participants will continue in their respective trials.
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
Xenon Pharmaceuticals announced the submission of a New Drug Application (NDA) to the FDA for azetukalner to treat focal seizures, based on positive data from Phase 2b and Phase 3 trials. The company also paused new patient enrollment in its psychiatry studies (MDD and BPD) due to observed neuropsychiatric adverse events, though current patients will continue, and the company aims to evaluate dosing modifications. Topline data for the X-NOVA2 study in MDD is now expected in Q1 2027.
Xenon pauses new enrollment in depression drug trials over side-effect concerns
Xenon Pharmaceuticals has temporarily halted new patient enrollment in clinical trials for its experimental depression drug due to reports of mental and nervous system-related side effects, including confusion, speech difficulties, and rare cases of psychosis. Shares of Xenon tumbled over 25% following the announcement. The company is evaluating potential dose adjustments and emphasized that its epilepsy program for the same drug remains unaffected, with an FDA application already submitted for focal seizures.
Xenon to Present at Wells Fargo Healthcare Conference
Xenon Pharmaceuticals Inc. announced its upcoming presentation at the Wells Fargo Healthcare Conference in Boston, MA. The company will participate in a fireside chat on Wednesday, September 9, from 11:00-11:30 am ET. Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing therapeutics for epilepsy, major depressive disorder, and bipolar depression.
Xenon to Present at Wells Fargo Healthcare Conference
Xenon Pharmaceuticals Inc. announced its participation in the upcoming Wells Fargo Healthcare Conference, where it will host a fireside chat on Wednesday, September 9, from 11:00–11:30 am ET. The neuroscience-focused biopharmaceutical company will provide details about its presentation and webcast information on the Investors section of its website. Xenon is currently advancing azetukalner, a KV7 potassium channel opener, in late-stage clinical development for neurological disorders, alongside other early-stage potassium and sodium channel modulators.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced equity inducement grants to five new non-officer employees. These grants consist of 13,450 share options and 7,850 restricted share units (RSUs), approved by the Compensation Committee with an effective date of August 27, 2026. The grants serve as inducements for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Xenon Pharmaceuticals to present epilepsy drug data at congress
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced it will present data on its epilepsy drug candidate, azetukalner, at the 16th European Epilepsy Congress in Athens, Greece, from September 5-9, 2026. The presentations will include results from the Phase 3 X-TOLE2 study for focal onset seizures, long-term data from the X-TOLE Open Label Extension study, and mechanistic characterization of azetukalner's potential additive effects with other antiseizure medications. Azetukalner is a potassium channel opener being developed for epilepsy, major depressive disorder, and bipolar depression.
Bank of America Corp DE Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE
Bank of America Corp DE has increased its stock holdings in Xenon Pharmaceuticals Inc. by 19.8% during the first quarter, now owning 265,267 shares valued at $15.42 million. Other institutional investors have also adjusted their positions in XENE, with hedge funds and institutional investors collectively owning 95.45% of the stock. Despite a recent trading dip, analysts maintain a "Buy" consensus rating for Xenon Pharmaceuticals, with an average target price of $77.13.
Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?
Xenon Pharmaceuticals Inc. reported wider Q2 2026 losses, with a net loss of US$110.74 million, as it invests heavily in its ion-channel neurology pipeline. The increased losses highlight the company's funding needs and the potential for dilution as it moves towards commercializing its lead epilepsy drug, azetukalner, and building out its commercial infrastructure. Investors are advised to consider how these rising costs impact the company's investment narrative, particularly with upcoming milestones like the planned U.S. NDA submission for azetukalner.
Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?
Xenon Pharmaceuticals recently reported wider Q2 2026 losses, reaching US$110.74 million, as it funds its ion-channel neurology pipeline, particularly ahead of the planned U.S. NDA submission for azetukalner. These rising losses bring funding needs and potential dilution into focus, prompting investors to assess the company's transition from an R&D focus to an early commercial stage. Despite these challenges, analysts project significant revenue growth and a fair value suggesting a 28% upside.
Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?
Xenon Pharmaceuticals Inc. (XENE) reported wider Q2 2026 net losses of US$110.74 million, funding its neurology pipeline. The company's investment narrative hinges on azetukalner's success, with upcoming catalysts like a U.S. NDA submission and a presence at Stifel’s 2026 Biotech Summer Summit. While analysts project significant revenue growth and a fair value upside, the increasing losses highlight ongoing funding needs and potential dilution risks for investors.
TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE
TimesSquare Capital Management LLC has acquired 451,593 shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a new position valued at approximately $27.3 million, giving them a 0.47% stake in the biopharmaceutical company. Institutional investors collectively own 95.45% of the stock. Xenon Pharmaceuticals recently reported better-than-expected quarterly adjusted EPS and maintains a "Buy" consensus rating from analysts, despite recent insider share sales.
Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds
Xenon Pharmaceuticals (XENE) recently reported a Q2 net loss of US$110.74 million but is considered 22.6% undervalued, with a fair value of $80.56 compared to its current price of $62.35. This valuation is driven by expectations for its epilepsy drug azetukalner, despite risks if clinical data disappoints or rival therapies emerge. The company's P/B ratio of 4.9x is high compared to the US Biotechs average but low compared to its peers.
Xenon Pharmaceuticals Independent Director Steven Gannon Sells 84% Of Holding
Xenon Pharmaceuticals' Independent Director Steven Gannon recently sold a significant 84% of his holdings, amounting to US$641k worth of stock. This follows another substantial sale by President Ian Mortimer in the last year, suggesting insiders might view lower prices as reasonable. While insider selling can be a cautionary signal, it's noted that the company's insiders hold a relatively small percentage of shares overall.
Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE
Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling about $774,000. Xenon Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on neurological and pain disorders, reported better-than-expected quarterly EPS.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from seventeen brokerages, with an average 12-month price target of $77.13. The company's stock is currently trading below its recent high, with institutional investors holding a significant 95.45% stake. Recent insider selling has also been noted, with key directors selling shares worth approximately $774,000 in the last three months.
Xenon Pharmaceuticals Director Sold Shares Worth Over $640K
Steven Gannon, a Director at Xenon Pharmaceuticals (XENE), reported the sale of common shares totaling $640,550 on August 11, 2026. The transactions were executed at a weighted-average price of $64.055 per share. Following this sale, Gannon directly holds 1,870 common shares in the company.
Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct
Director Steven Gannon of Xenon Pharmaceuticals (XENE) sold 10,000 shares for $64.06 per share, totaling $640,600, reducing his direct holdings to 1,870 shares. This sale contributes to a broader trend of 13 insider sells and no buys over the past year at Xenon, signaling potential caution, although some institutional investors are increasing their stakes. The company, a clinical-stage biopharmaceutical firm, is valued at $6.21 billion and is developing therapeutics for neurological disorders.
Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients
Wellington Management Group LLP and its affiliates have reported a passive ownership stake of approximately 1.47% in Xenon Pharmaceuticals Inc. (XENE) common stock. This stake, representing 1,425,492 shares, is held for advisory clients across various Wellington investment entities, with no single client owning more than five percent. The filing indicates shared voting and dispositive power over these securities, emphasizing their role as investment advisers.
Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64
Xenon Pharmaceuticals director Steven Gannon sold 10,000 Common Shares on August 11, 2026, at a weighted-average price of $64.055 per share. The shares were sold in multiple transactions ranging from $64.0517 to $64.078. Following this transaction, Gannon directly holds 1,870 Common Shares of Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. Q2 2026: Revenue $0 EPS $(1.11) — 10-Q Summary
Xenon Pharmaceuticals Inc. reported its Q2 2026 financial results, showing no product or collaboration revenue and a net loss of $110.7 million, or $(1.11) diluted loss per share. This represents a wider net loss compared to Q2 2025, primarily due to increased R&D spending and operational build-out for late-stage clinical programs. Despite the losses, the company maintains strong cash balances to support ongoing development and planned trial completions.
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy
H.C. Wainwright maintained a Buy rating and a $74.00 price target for Xenon Pharmaceuticals (NASDAQ: XENE), citing the FDA's lack of concerns regarding their pre-NDA meeting and the company's belief that their drug package supports approval of all four doses. The stock has seen an 89.5% return over the past year, and the company is actively preparing its launch infrastructure for eventual approval. Additionally, the article mentions 10x Genomics, which reported better-than-expected Q2 2026 results and raised its full-year revenue outlook, driven by strong demand for its new Atera spatial platform.
HC Wainwright Issues Positive Outlook for XENE Earnings
HC Wainwright has revised its earnings outlook for Xenon Pharmaceuticals (NASDAQ:XENE), predicting reduced losses for Q3 2026 and subsequent fiscal years, and maintaining a "Buy" rating with a $74 price target. The biopharmaceutical company recently surpassed analyst expectations for its quarterly loss. Despite these positive revisions, Xenon Pharmaceuticals is still forecast to remain unprofitable through 2029, though the improved long-term outlook suggests a trajectory toward breakeven.
